glp·helper
glphelper.com/zepbound/nebraska/omaha
Dual GIP / GLP-1 receptor agonistFDA-approved November 2023Rx · Subcutaneous injection · Once weekly

Zepbound® providers &
prescriptions in Omaha, NE

Verified Zepbound providers in Omaha, NE. Checked against the NPI registry, sorted by waitlist, not by who pays us.[7]

average Zepbound weight loss →trial-anchored estimate
city providers
34
as of today
median wait
8d
first visit
telehealth
71%
of providers
cash range
$25 to $1,150
monthly
§ 02Provider directory: Nebraska
34 of 34 shown

Find a Zepbound provider in Nebraska.

Every entry is checked against the NPI registry and the Nebraska medical board. Listings are ordered by current waitlist. The provider who can see you fastest appears first. We do not accept payment for placement.

Filter →
Type
Provider
City
Waitlist
Insurance
Browse by Nebraska city · /zepbound/nebraska/{city}
§ 03Getting Zepbound in Omaha
34 providers · Omaha, NE

How to get Zepbound in Omaha.

34 GLP-1 prescribers and 7 local resource types are on record for Omaha, plus 1 nearby town in the directory.

Prescribers in Omaha
34 prescribers
34 GLP-1 prescribers in Omaha, most listed as Internal Medicine, Endocrinology, Diabetes & Metabolism (13), Family Medicine (12) and Internal Medicine (6). Any Nebraska-licensed physician, nurse practitioner, or PA can prescribe Zepbound, over video or in person. The nearest towns on record are Lincoln (30 providers).
Around the prescription in Omaha
7 listed nearby
6 dietitians, 6 nutritionists, 6 gyms, 5 fitness clubs, 6 trainers, 6 physiotherapists and 6 places to move are on record near Omaha.
Medicaid (weight loss)
Diabetes only
As of April 2026, Nebraska Medicaid covers GLP-1s for diabetes but not for weight loss. Employer and private plans can still cover them; that is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm Nebraska’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for chronic weight management in adults. Same molecule as Mounjaro.

Zepbound is the brand name Eli Lilly uses for tirzepatide approved for chronic weight management. It is a once-weekly subcutaneous injection and the first approved dual GIP/GLP-1 receptor agonist. The identical molecule, marketed as Mounjaro, is the FDA-approved formulation for type 2 diabetes.[2][3]

In SURMOUNT-1, adults with obesity (without diabetes) lost a mean of 20.9% of body weight on the 15 mg dose at 72 weeks, versus 3.1% with placebo. That is among the largest average weight reductions reported for an anti-obesity medication. Zepbound is approved as an adjunct to a reduced-calorie diet and increased physical activity.[1]

At a glanceMultiple (per dose)
Generic name
tirzepatide
Drug class
Dual GIP / GLP-1 receptor agonist
Manufacturer
Eli Lilly
FDA approved
November 2023
Approved use
Chronic weight management (adults with obesity, or overweight with a weight-related condition)
Off-label use
Type 2 diabetes (Mounjaro is the FDA-approved tirzepatide for diabetes)
Administration
Subcutaneous injection · Once weekly
Available doses
2.5 mg · 5 mg · 7.5 mg · 10 mg · 12.5 mg · 15 mg
Half-life
≈ 5 days
Pregnancy
Discontinue ≥ 2 months before a planned pregnancy; may reduce oral contraceptive efficacy

Community health · CDC

Weight & metabolic health in Nebraska

Diagnosed diabetes reaches 9.7% of adults in Nebraska.

of Nebraska adults have obesity
37.6%
diagnosed diabetes
9.7%

Age-adjusted estimates for Nebraska, community figures, not individual risk. CDC BRFSS 2024.

Estimate your weight lossthe GLP-1 side-effect timeline
§ 05Support around Zepbound in Omaha
5 fitness clubs

The prescription is one part. Here is the rest, in Omaha.

Trials of tirzepatide paired the drug with diet counseling and regular activity. Every name below is a real listing near Omaha, NE, ordered as the registry lists them, never by who pays us.

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

Papillion Landing Community Recreation Center
REC CENTER
4.5 on Google · 471 reviews
1046 W Lincoln St
Website
Life Time
FITNESS
3.9 on Google · 439 reviews
17007 Elm Plaza
Website
Jewish Community Center of Omaha
FITNESS
4.6 on Google · 271 reviews
333 S 132nd St
Website
Blue Moon Fitness
FITNESS
4.0 on Google · 229 reviews
8447 W Center Rd
Website
VASA Fitness
FITNESS
4.5 on Google · 205 reviews
909 Fort Crook Rd N
Website

Nutritionists

A nutritionist helps you get enough protein and fiber while the medication cuts your appetite. Call to ask what they cover.

Sherry Adams, RD
NUTRITIONIST
Nutritionist · Education
601 N 30Th St
Call 402-717-4869NPI 1265670582
Jordan Bontrager, RD LMNT
NUTRITIONIST
Nutritionist
6829 N 72Nd St Ste 4500
Call 402-717-1299NPI 1477184018
Amanda Caven
NUTRITIONIST
Nutritionist
19908 Madison St
Call 308-631-8680NPI 1255132619
Stephanie Dashiell, RD, LMNT
NUTRITIONIST
Nutritionist
8552 Cass St
Call 402-955-6799NPI 1407644370
Francine Hamburger, NTP
NUTRITIONIST
Nutritionist
3331 Hickory St
Call 402-213-4199NPI 1821701665
Mary Kardell, RD, LMNT
NUTRITIONIST
Nutritionist
21919 Pierce Cir
Call 402-630-7415NPI 1518177112
§ 06Clinical evidence
STEP 1 to 4 + SELECT (N = 17,604)

What the trials actually showed.

We summarize the SURMOUNT weight-management program. Figures are means at the 72-week primary endpoint, by dose.

SURMOUNT-1 randomized 2,539 adults with obesity (without diabetes) across 72 weeks. Mean weight change was −15.0% (5 mg), −19.5% (10 mg), and −20.9% (15 mg) versus −3.1% with placebo. A majority of patients on the higher doses lost ≥20% of body weight.[2]
STEP / SELECT endpoint table2.4 mg / 68 wk
Mean weight change (15 mg)
−20.9%
SURMOUNT-1, 72 wk vs −3.1% placebo[2]
Mean weight change (10 mg)
−19.5%
SURMOUNT-1, 72 wk[2]
Mean weight change (5 mg)
−15.0%
SURMOUNT-1, 72 wk[2]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Zepbound weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in STEP trials were nausea (44%), diarrhea (30%), and vomiting (24%), more frequent at the 2.4 mg dose than at Ozempic doses, but typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Boxed warning: risk of thyroid C-cell tumors. Contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
12 to 24%
mild
Dose-dependent; usually eases after titration
Diarrhea
12 to 19%
mild
More frequent during dose escalation
Vomiting
5 to 13%
mild
Reduced by slower titration
Constipation
6 to 17%
mild
Decreased appetite
5 to 11%
mild
Expected pharmacologic effect
Pancreatitis
<0.3%
serious
Discontinue if acute pancreatitis is suspected
Gallbladder disease
~1 to 2%
serious
Cholelithiasis risk rises with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated with MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Zepbound cash price (no insurance)
$1,000 to $1,300
per month
Brand-name retail; Lilly self-pay vials lower for some doses[6]
Commercial insurance (weight)
Often denied
On-label for obesity but frequently requires prior authorization
Medicare Part D
Not covered
Weight-loss indication not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial insurance with coverage only; eligibility limits apply
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Zepbound providers in Nebraska

NPI-verified Zepbound (tirzepatide) prescribers and clinics, ordered by availability, never by who pays us.

Zepbound in other states

Find NPI-verified Zepbound (tirzepatide) doctors, clinics, and pharmacies in the states we cover, ordered by availability, never by who pays us.

Related GLP-1 research
§ 09Frequently asked: Zepbound in Nebraska

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Zepbound and Mounjaro are both tirzepatide, made by Eli Lilly, but they carry different FDA-approved indications. Zepbound is approved for chronic weight management; Mounjaro is approved for type 2 diabetes. Insurers treat them as separate products, and weight-loss coverage is far more restricted than diabetes coverage.[1]